Cost-Effectiveness of Dapagliflozin in the Treatment of Patients With Chronic Kidney Disease in Denmark
Thea Tanderup Kjær, Morten Lindhardt, Anders Hammerich Riis, Henrik Birn, Lars Holger Ehlers · 2026
Read Cost-Effectiveness of Dapagliflozin in the Treatment of Patients With Chronic Kidney Disease in Denmark by Thea Tanderup Kjær, Morten Lindhardt, Anders Hammerich Riis, Henrik Birn, Lars Holger Ehlers (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13634386.txt.
Description
Rationale & ObjectiveChronic kidney disease (CKD) is a growing burden worldwide and in Denmark, with substantial clinical and economic consequences. Although national guidelines recommend sodium/glucose transporter 2 inhibitors (SGLT2i) for patients with CKD, type 2 diabetes (T2D) or heart failure (HF), underdiagnosis limits the use of SGLT2i.
Catalog record
| CREATOR | Thea Tanderup Kjær, Morten Lindhardt, Anders Hammerich Riis, Henrik Birn, Lars Holger Ehlers |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |